Cargando…
Study Design Selection in Early Clinical Anti‐Hyperglycemic Drug Development: A Simulation Study of Glucose Tolerance Tests
In antidiabetic drug development, phase I studies usually involve short‐term glucose provocations. Multiple designs are available for these provocations (e.g., meal tolerance tests (MTTs) and graded glucose infusions (GGIs)). With a highly nonlinear, complex system as the glucose homeostasis, the va...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063744/ https://www.ncbi.nlm.nih.gov/pubmed/29732710 http://dx.doi.org/10.1002/psp4.12302 |
_version_ | 1783342600925741056 |
---|---|
author | Ibrahim, Moustafa M. A. Ghadzi, Siti M. S. Kjellsson, Maria C. Karlsson, Mats O. |
author_facet | Ibrahim, Moustafa M. A. Ghadzi, Siti M. S. Kjellsson, Maria C. Karlsson, Mats O. |
author_sort | Ibrahim, Moustafa M. A. |
collection | PubMed |
description | In antidiabetic drug development, phase I studies usually involve short‐term glucose provocations. Multiple designs are available for these provocations (e.g., meal tolerance tests (MTTs) and graded glucose infusions (GGIs)). With a highly nonlinear, complex system as the glucose homeostasis, the various provocations will contribute with different information offering a rich choice. Here, we investigate the most appropriate study design in phase I for several hypothetical mechanisms of action of a study drug. Five drug effects in diabetes therapeutic areas were investigated using six study designs. Power to detect drug effect was assessed using the likelihood ratio test, whereas precision and accuracy of the quantification of drug effect was assessed using stochastic simulation and estimations. An overall summary was developed to aid designing the studies of antihyperglycemic drug development using model‐based analysis. This guidance is to be used when the integrated glucose insulin model is used, involving the investigated drug mechanisms of action. |
format | Online Article Text |
id | pubmed-6063744 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-60637442018-07-31 Study Design Selection in Early Clinical Anti‐Hyperglycemic Drug Development: A Simulation Study of Glucose Tolerance Tests Ibrahim, Moustafa M. A. Ghadzi, Siti M. S. Kjellsson, Maria C. Karlsson, Mats O. CPT Pharmacometrics Syst Pharmacol Research In antidiabetic drug development, phase I studies usually involve short‐term glucose provocations. Multiple designs are available for these provocations (e.g., meal tolerance tests (MTTs) and graded glucose infusions (GGIs)). With a highly nonlinear, complex system as the glucose homeostasis, the various provocations will contribute with different information offering a rich choice. Here, we investigate the most appropriate study design in phase I for several hypothetical mechanisms of action of a study drug. Five drug effects in diabetes therapeutic areas were investigated using six study designs. Power to detect drug effect was assessed using the likelihood ratio test, whereas precision and accuracy of the quantification of drug effect was assessed using stochastic simulation and estimations. An overall summary was developed to aid designing the studies of antihyperglycemic drug development using model‐based analysis. This guidance is to be used when the integrated glucose insulin model is used, involving the investigated drug mechanisms of action. John Wiley and Sons Inc. 2018-05-06 2018-07 /pmc/articles/PMC6063744/ /pubmed/29732710 http://dx.doi.org/10.1002/psp4.12302 Text en © 2018 The Authors CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Research Ibrahim, Moustafa M. A. Ghadzi, Siti M. S. Kjellsson, Maria C. Karlsson, Mats O. Study Design Selection in Early Clinical Anti‐Hyperglycemic Drug Development: A Simulation Study of Glucose Tolerance Tests |
title | Study Design Selection in Early Clinical Anti‐Hyperglycemic Drug Development: A Simulation Study of Glucose Tolerance Tests |
title_full | Study Design Selection in Early Clinical Anti‐Hyperglycemic Drug Development: A Simulation Study of Glucose Tolerance Tests |
title_fullStr | Study Design Selection in Early Clinical Anti‐Hyperglycemic Drug Development: A Simulation Study of Glucose Tolerance Tests |
title_full_unstemmed | Study Design Selection in Early Clinical Anti‐Hyperglycemic Drug Development: A Simulation Study of Glucose Tolerance Tests |
title_short | Study Design Selection in Early Clinical Anti‐Hyperglycemic Drug Development: A Simulation Study of Glucose Tolerance Tests |
title_sort | study design selection in early clinical anti‐hyperglycemic drug development: a simulation study of glucose tolerance tests |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063744/ https://www.ncbi.nlm.nih.gov/pubmed/29732710 http://dx.doi.org/10.1002/psp4.12302 |
work_keys_str_mv | AT ibrahimmoustafama studydesignselectioninearlyclinicalantihyperglycemicdrugdevelopmentasimulationstudyofglucosetolerancetests AT ghadzisitims studydesignselectioninearlyclinicalantihyperglycemicdrugdevelopmentasimulationstudyofglucosetolerancetests AT kjellssonmariac studydesignselectioninearlyclinicalantihyperglycemicdrugdevelopmentasimulationstudyofglucosetolerancetests AT karlssonmatso studydesignselectioninearlyclinicalantihyperglycemicdrugdevelopmentasimulationstudyofglucosetolerancetests |